# HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

> **NCT01683188** · PHASE4 · TERMINATED · sponsor: **Clinigen, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** vemurafenib + HD IL-2

## Key facts

- **NCT ID:** NCT01683188
- **Lead sponsor:** Clinigen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** slow accrual led to early closure.
- **Last updated:** 2021-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01683188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01683188, "HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01683188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*